docetaxel anhydrous has been researched along with pf 3084014 in 4 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (pf 3084014) | Trials (pf 3084014) | Recent Studies (post-2010) (pf 3084014) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 46 | 7 | 43 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | pf 3084014 (IC50) |
|---|---|---|---|
| Presenilin-1 | Homo sapiens (human) | 0.0068 | |
| Presenilin-2 | Homo sapiens (human) | 0.0068 | |
| Gamma-secretase subunit APH-1B | Homo sapiens (human) | 0.0068 | |
| Nicastrin | Homo sapiens (human) | 0.0068 | |
| Gamma-secretase subunit APH-1A | Homo sapiens (human) | 0.0068 | |
| Gamma-secretase subunit PEN-2 | Homo sapiens (human) | 0.0068 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, E; Christensen, JG; Fang, DD; John-Baptiste, A; Lira, ME; Painter, C; Yan, Z; Zhang, CC; Zhang, Q; Zong, Q | 1 |
| Cui, D; Dai, J; Keller, ET; Keller, JM; Mizokami, A; Xia, S | 1 |
| Aftimos, P; Awada, A; Cesari, R; Curigliano, G; Dees, EC; Huang, B; Jiang, Y; Kern, KA; Locatelli, MA; LoRusso, PM; Pegram, MD; Shaik, MN | 1 |
| Chen, Z; Du, Z; Hao, Y; Li, L; Li, T; Liu, N; Luo, C; Quan, Z; Sun, W; Wang, J; Wang, X; Wu, X; Yuan, M; Zhang, Y | 1 |
1 trial(s) available for docetaxel anhydrous and pf 3084014
| Article | Year |
|---|---|
Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Taxoids; Tetrahydronaphthalenes; Triple Negative Breast Neoplasms; Valine; Vomiting | 2017 |
3 other study(ies) available for docetaxel anhydrous and pf 3084014
| Article | Year |
|---|---|
Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models.
Topics: AC133 Antigen; Amyloid Precursor Protein Secretases; Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytokines; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Glycoproteins; Humans; Hyaluronan Receptors; Membrane Proteins; Mice; Mice, SCID; Multidrug Resistance-Associated Protein 2; Nerve Tissue Proteins; Peptides; Receptor, Notch1; Signal Transduction; Taxoids; Tetrahydronaphthalenes; Time Factors; Valine; Xenograft Model Antitumor Assays | 2013 |
Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer.
Topics: Amyloid Precursor Protein Secretases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Docetaxel; Drug Synergism; Humans; Male; Mice; Mice, Inbred NOD; NF-kappa B; Prostatic Neoplasms; Signal Transduction; Taxoids; Tetrahydronaphthalenes; Valine; Xenograft Model Antitumor Assays | 2015 |
HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in
Topics: Adult; Aged; Amyloid Precursor Protein Secretases; Benzamides; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate; Prostatic Neoplasms, Castration-Resistant; Proteins; Receptors, Notch; Signal Transduction; Taxoids; Tetrahydronaphthalenes; Valine; Xenograft Model Antitumor Assays | 2018 |